Matching articles for "Perseris"

In Brief: Three New Injectable Antipsychotic Drugs

   
The Medical Letter on Drugs and Therapeutics • December 25, 2023;  (Issue 1692)
Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the...
Three extended-release injectable formulations of second-generation antipsychotic drugs — two of risperidone (Rykindo, Uzedy) and one of aripiprazole (Abilify Asimtufii) — have been approved by the FDA for treatment of schizophrenia in adults. Rykindo and Abilify Asimtufii are also approved for maintenance treatment of bipolar I disorder in adults. Other extended-release injectable formulations of risperidone and aripiprazole have been available in the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8 | Show Full IntroductionHide Full Introduction